Quarterly ResultAug 5, 2026, 04:09 PM
PacBio Q2 Revenue $39.0M; GAAP Net Loss $(44.7)M
AI Summary
PacBio announced Q2 2026 financial results with total revenue of $39.0 million, a slight decrease from $39.8 million in Q2 2025. The company reported a GAAP net loss of $(44.7) million and a non-GAAP net loss of $(41.9) million for the quarter, both higher than the previous year. Despite the decline in overall revenue, consumable revenue grew to $20.1 million, and Revio system placements increased. PacBio also commenced the global commercial rollout of its SPRQ-Nx chemistry and implemented restructuring actions to enhance efficiency. The company provided full-year 2026 revenue guidance of $155 million to $165 million.
Key Highlights
- Total revenue for Q2 2026 was $39.0 million, a decrease from $39.8 million in Q2 2025.
- GAAP net loss for Q2 2026 was $(44.7) million, compared to $(41.9) million in Q2 2025.
- Non-GAAP net loss for Q2 2026 was $(41.9) million, compared to $(40.0) million in Q2 2025.
- Consumable revenue increased to $20.1 million in Q2 2026 from $18.9 million in Q2 2025.
- Commenced global commercial rollout of SPRQ-Nx chemistry, delivering whole genome sequencing at $345 USD.
- Implemented restructuring actions to streamline marketing and R&D organizations and strengthen commercial efforts.
- Revio system placements increased to 20 in Q2 2026 from 15 in Q2 2025.
- Full year 2026 revenue guidance is projected to be in the range of $155 million to $165 million.
Price Impact
More from PACB